financetom
Business
financetom
/
Business
/
LNG Canada begins production at second unit, company says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
LNG Canada begins production at second unit, company says
Nov 6, 2025 11:04 AM

CALGARY, Nov 6 (Reuters) - LNG Canada has started

production of liquefied natural gas at the second of its

two processing units, known as Train 2, the company said.

Both trains at the Shell-led project in Kitimat,

British Columbia - each with a capacity of 6.5 million metric

tons per annum - are now operational, a spokesperson told

Reuters.

LNG Canada is the first major LNG export facility in Canada and

the first on the west coast of North America that provides

direct access to Asia, the world's largest market for the liquid

fuel. When fully operational, the facility is expected to

process about two billion cubic feet of gas per day.

LNG Canada, which took almost seven years to build, shipped its

first cargo on June 30. However, technical challenges have made

the ramp-up slower than many analysts expected.

A 22nd LNG cargo departed the LNG Canada facility on Thursday

for export to global markets, the spokesperson said.

Market participants have expressed hope that the startup of the

second train will create enough demand to reduce the glut of

natural gas in storage in Western Canada and help lift prices.

LNG Canada is a joint venture between Shell, Malaysia's Petronas

PGAS.KL, PetroChina, Japan's Mitsubishi Corp ( MSBHF )

, and South Korea's KOGAS.

Last month, MidOcean - an LNG company backed by EIG and Saudi

Aramco - announced a plan to buy a fifth of the Petronas venture

that holds a 25% share of LNG Canada.

(Reporting by Amanda Stephenson in Calgary and Curtis Williams

in Houston; Editing by Nathan Crooks and Emelia

Sithole-Matarise)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Actor Jonathan Majors avoids jail after domestic violence conviction
Actor Jonathan Majors avoids jail after domestic violence conviction
Apr 8, 2024
NEW YORK, April 8 (Reuters) - Jonathan Majors, a fast-rising Hollywood star before domestic violence charges derailed his career, avoided jail and was sentenced to one year of domestic-violence counseling on Monday after being found guilty of attacking his former girlfriend. The sentence was imposed by Justice Michael Gaffey of the state Supreme Court in Manhattan, where Majors was convicted...
Southey Capital offers to buy shares in Russian railroad firm Globaltrans
Southey Capital offers to buy shares in Russian railroad firm Globaltrans
Apr 8, 2024
* This content was produced in Russia where the law restricts coverage of Russian military operations in Ukraine MOSCOW, April 8 (Reuters) - Southey Capital, a capital markets firm specialising in distressed and illiquid securities, said on Monday it was offering to buy shares in Russian railroad operator Globaltrans at a discount of around 20%. Western sanctions imposed in response...
Eyenovia to Weigh Potential Sale, Other Strategic Alternatives
Eyenovia to Weigh Potential Sale, Other Strategic Alternatives
Apr 8, 2024
11:35 AM EDT, 04/08/2024 (MT Newswires) -- Eyenovia ( EYEN ) said Monday it has launched a process to explore potential strategic alternatives, including an outright company sale, in order to maximize shareholder value. The commercial-stage ophthalmic company said its strategic options also include an asset sale or merger and that it is in contact with investment banks to help...
Shanghai Henlius Biotech Denosumab Biosimilar HLX14 Meets Endpoint
Shanghai Henlius Biotech Denosumab Biosimilar HLX14 Meets Endpoint
Apr 8, 2024
11:43 AM EDT, 04/08/2024 (MT Newswires) -- Shanghai Henlius Biotech and Organon (OGN) said Monday that the phase 3 study for the investigational Prolia and Xgeva (denosumab) biosimilar HLX14 met the primary endpoints. The study aimed to compare the efficacy, safety, tolerability, and immunogenicity of HLX14 with EU-sourced reference denosumab (Prolia(r)) in postmenopausal women with osteoporosis at high risk for...
Copyright 2023-2026 - www.financetom.com All Rights Reserved